Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Medicure (NGQ1) Stock Price & Analysis

0 Followers

NGQ1 Stock Chart & Stats

€2.38€0.02(0.85%)
At close: 5:30 PM GMT+1
€1€1.5€2Aug 28Sep 9Sep 29Oct 9Oct 26
Day’s Range
EUR 2.38 - EUR 2.38
52-Week Range
EUR 0.55 - EUR 2.84
Previous Close
EUR 2.36
Volume
N/A
Average Volume (3M)
105
Market Cap
EUR 24.42M
Enterprise Value
EUR 12.33M
Total Cash (Recent Filing)
EUR 1.83M
Total Debt (Recent Filing)
EUR 696.00K
Price to Earnings (P/E)
―
Beta
0.71
Next Earnings
Nov 25, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Conservative Balance Sheet

Debt is modest relative to equity and assets, reducing near-term financing pressure while leaving more flexibility to support operations or strategic investment. This conservative structure is a durable buffer as the company works to restore profitability and cash generation.

Revenue Growth

TTM revenue reached $32.1M and grew 2.4%, showing that Medicure continues to generate demand despite its current losses. Continued top-line expansion can provide a base for operating leverage if product mix, pricing, or cost discipline improves over coming quarters.

Focused Specialty Healthcare Model

Medicure operates in specialty pharmaceuticals, with cardiovascular and related hospital and acute-care therapies, and sells through U.S. operations to hospitals and providers. This focused healthcare model gives the company an identifiable therapeutic and institutional customer base.

Bears Say

Persistent Losses And Negative Margins

TTM net loss of $7.45M and EBIT and EBITDA margins of about -21% and -13% show that the current revenue base does not cover operating costs. Persistent losses weaken retained capital and make growth less valuable unless profitability improves over the next several quarters.

Negative Cash Generation

Operating and free cash flow were both -$1.93M TTM, reversing positive cash generation in 2023–2024. Ongoing cash consumption reduces self-funding capacity and can increase dependence on liquidity or external funding, limiting resilience if losses persist.

Weaker Economics And Shrinking Equity Cushion

Gross margin has fallen to about 40% TTM from much stronger levels in 2022–2024, while ROE is around -55% and equity has declined from 2024. The combination points to weaker economics and a shrinking shareholder cushion unless performance recovers.

Medicure News

NGQ1 FAQ

What was Medicure’s price range in the past 12 months?
Medicure lowest stock price was €0.55 and its highest was €2.84 in the past 12 months.
What is Medicure’s market cap?
Medicure’s market cap is €24.42M.
When is Medicure’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Medicure’s earnings last quarter?
Medicure released its earnings results on Aug 14, 2026. The company reported -€0.085 earnings per share for the quarter.
Is Medicure overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Medicure pay dividends?
Medicure does not currently pay dividends.
What is Medicure’s EPS estimate?
Medicure’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Medicure have?
Medicure has 10,436,313 shares outstanding.
What happened to Medicure’s price movement after its last earnings report?
Medicure reported an EPS of -€0.085 in its last earnings report. Following the earnings report the stock price went up 1.282%.
Which hedge fund is a major shareholder of Medicure?
Currently, no hedge funds are holding shares in DE:NGQ1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology